Evidence map›Paper›PMID 40082209›Full record

ReviewChemMedChem2025

Corrin Ring Modification in Peptide Drug Development - a Brief History of "Corrination".

Nancy Cham, Robert P Doyle

Abstract readReview
In one paragraph

Review in ChemMedChem, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Nancy ChamDepartment of Chemistry, Syracuse University, 111 College Place, Syracuse, NY, 13244, USA.
Robert P DoyleDepartment of Chemistry, Syracuse University, 111 College Place, Syracuse, NY, 13244, USA.ORCID https://orcid.org/0000-0001-6786-5656

Funding

Second generation GLP-1 agonists without nausea/emesis side effectsR01DK128443 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI DE JONGHE, BART C, DOYLE, ROBERT P · 2021 to 2024
$2.4M
National Institute of Health (NIDDK) R01DK128443NIDDK NIH HHS R01 DK128443
6 · The paper itself

Abstract

Recently, the term "corrination" was coined to describe the conjugate modification of a peptide, protein, small molecule, or radionuclide with a corrin ring-containing molecule. By exploiting the innate chemicophysical properties of corrin ring-containing compounds, corrination has been explored for drug development and targeted/localized delivery of probes and therapeutics. Most recently, it is in the field of peptide-based therapeutics that corrination is generating significant interest. Peptide-based drugs possess several limitations that restrict their clinical application, including poor solubility and stability, low oral bioavailability, and negative side effects often due to drug distribution. In this mini review, the design and synthetic approaches to peptide corrination are described, along with examples of in vitro, ex vivo, and in vivo biological evaluations of corrinated conjugates, which demonstrate the broad applicability of the technique, namely 1) mitigated peptide aggregation, 2) improved protection against proteolysis, 3) reduced negative side effects via targeted localization, 4) regioselective production of peptide disulfide bonds, and 5) improved oral drug absorption. Herein, it is described how corrination offers a facile route to improving peptide pharmacokinetic and pharmacodynamic properties, making this a useful platform technology in the field of peptide drug development.

Indexed as

Drug DevelopmentPeptidesAnimalsHumansMolecular StructurePeptidescobinamidecorrinationcorrin ringpeptidesvitamin B12

Identifiers

PMID40082209
PMCPMC12091844

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.